Market Size of Von Willebrand Disease Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Von Willebrand Disease Treatment Market Analysis
The Von Willebrand disease (VWD) treatment market is expected to register a CAGR of 6.5% during the forecast period.
The COVID-19 pandemic significantly impacted the studied market. As per a research article published in the ALM journal in September 2021, patients with COVID-19 significantly elevated levels of the von Willebrand factor (vWF) antigen, contributing to an increased risk of thrombosis that was seen in COVID-19-associated coagulopathy (CAC). As per the same source, the high levels of vWF antigen and activity have been clinically correlated with worse outcomes. Thus, it created opportunities for the availability of VWD treatment and impacted the market considerably. Therefore, COVID-19 impacted the studied market significantly and is expected to continue its strong growth over the forecast period.
Factors such as increased patient assistance programs and growing healthcare expenditure are expected to fuel the market's growth during the forecast period.
In July 2021, the PAN Foundation opened a new patient assistance program for people with VWD. The patients who qualify for this program receive USD 10,200 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with the treatment for the disease. Another initiative is the Octapharma Co-Pay Assistance Program. This program is available through Factor My Way and provides eligible patients with significant savings on some of the costs associated with their treatment. Such programs propel the demand for treating Von Willebrand's disease, contributing to the market's growth.
Furthermore, the incidence and prevalence of VWD disease are increasing globally and creating new opportunities for developing new drugs, therapies, and treatments available in the market. For instance, according to the Clinical guidelines for VWD published in January 2021 by the World Federation of Hemophilia (WFH), the annual prevalence of VWD ranges from 1 in 100 to 1 in 10,000 globally and requires medical attention for bleeding.
In addition, as per a research study published in the Journal of Blood Medicine in March 2023, approximately 0.6% - 1.3% of the general population was affected by VWD, and the prevalence of symptomatic VWD was approximately 10 per 100,000 during the study period of the research. This disease burden is attracting the focus of government bodies and market players toward the investments and development of innovative drugs, contributing to the studied market growth. Thus, the market is expected to grow over the forecast period due to the abovementioned factors.
However, the need for more awareness and the high cost of the treatment are the factors hindering the market growth.
